Figure 3.

Effect of canagliflozin* on (A) systolic blood pressure; (B) pulse; (C) body weight; (D) haemoglobin A1c; (E) urinary albumin‐to‐creatinine ratio; (F) serum uric acid; and (G) haematocrit in participants in the CANVAS Program, stratified by baseline use of any diuretic. *Calculated as mean change from baseline across the entire follow‐up period. The average change in these continuous outcomes from baseline by canagliflozin treatment and the difference in treatment effect between those on and not on diuretics at baseline were analysed using mixed‐effect models for repeated measures including all data up to Week 312 and covariates for study, visit, treatment, baseline measures, treatment‐by‐visit, and baseline‐by‐visit interactions.